Home / Business and Economy / Lupin Bets Big on Innovation, Eyes 'Very Different Story' Next Year
Lupin Bets Big on Innovation, Eyes 'Very Different Story' Next Year
15 Mar
Summary
- Lupin is pivoting to innovation with a substantial focus on proprietary products.
- The company is investing in new chemical entities (NCEs) for both global and Indian markets.
- Lupin will launch two semaglutide products after patent expiry this week.
Drugmaker Lupin is strategically shifting its focus towards innovation, with Managing Director Nilesh Gupta anticipating a significantly transformed business profile within the next year. This pivot involves a substantial commitment to proprietary products, a move unprecedented for the company in India.
Lupin's innovation strategy is twofold, encompassing development for the global market and tailored solutions for India. The company is investing in new chemical entities (NCEs) for various therapeutic areas, including cardiac, diabetes, respiratory, and oncology. Developing NCEs specifically for the Indian market offers advantages like lower costs and shorter timelines.
Furthermore, Lupin is increasing its investments in technology, recognizing artificial intelligence as a crucial element for future impact. This aggressive push into innovation aims for "innovation at scale." The company also confirmed the launch of two semaglutide products on March 15, 2026, immediately following the patent expiration of the active ingredient used in popular diabetes and weight-loss drugs. This move is expected to significantly reduce medication costs for Indian consumers.
